Scientific & Clinical Advisory Board
Edith Mathiowitz, Ph.D.
Dr. Mathiowitz is tenured Professor of Medical Science and Engineering, and the Director of the Artificial Organs, Biomaterials and Cellular Technology graduate program at Brown University’s Department of Molecular Pharmacology, Physiology & Biotechnology. She received her Ph.D. in Polymer Chemistry from the Weizmann Institute of Science in Israel and did her Post-doctoral fellowship in drug delivery with Professor Robert Langer at MIT. Dr. Mathiowitz is the Inventor and co-Inventor of TherapyX’s core patents licensed from Brown University. She worked at Enzytech (now Alkermes) and was one of the developers of the Prolease® drug delivery technology. Dr. Mathiowitz founded Spherics Inc. in 1997 and served as its Chairperson and Member of its Scientific Advisory Board. She served as a 2005 co-chair of the Controlled Release Society, the leading international organization on drug delivery. Dr. Mathiowitz founded Perosphere Inc. in 2011 and served as its Chief Scientific Officer. She also currently serves as a Member of the Scientific Advisory Board of Perosphere and Freedom-2, Inc. Dr. Mathiowitz has played a critical role in the development of TherapyX’s EXStaM (Patent Pending) technology.
Charles O. Elson, M.D.
An internationally recognized expert and leading authority in Inflammatory Bowel Disease research, Dr. Elson is Professor of Medicine and Microbiology and the Basil I. Hirschowitz Chair in Gastroenterology at University of Alabama at Birmingham. He is also a member of the Advisory Council of the National Institute of Diabetes and Digestive and Kidney Diseases. His laboratory pioneered the development of numerous mouse models of inflammatory bowel disease, including murine DSS and TNBS colitis models. Dr. Elson advises the Company on the IBD program.
Peter J. Mannon, M.D., M.P.H.
Dr. Mannon received his M.D. from Boston University and completed his clinical fellowships in gastroenterology at Duke University Medical Center and the Johns Hopkins Medical Center and served as Chief, Gastroenterology Section at Durham VA Medical Center. He then served as Head, Clinical Inflammatory Bowel Diseases Research Unit at the Mucosal Immunology Section, NIAID/NIH. Dr. Mannon is currently Professor of Medicine and Microbiology, Director of Gastroenterology/Hepatology Clinical Research Program and Director of UAB IBD Center at University of Alabama, Birmingham. Dr. Mannon was the lead author on the first report of anti-p40 use in Crohn’s disease, of a pilot study using G-CSF and identifying induction of regulatory T cells in successfully treated Crohn’s patients, and of a report documenting significant inhibition of IL-13 in UC patients treated with interferon-β (data which was used as the basis for a multinational Phase II study funded by Biogen). During his tenure at the NIH, Dr. Mannon led the effort to establish the Clinical Inflammatory Bowel Diseases Research Unit in the Mucosal Immunity Section of the NIH Intramural Program. He subsequently established the UAB IBD Center and serves as lead investigator on several clinical trials. His expertise is critical to the clinical evaluation TrexTAM.